Back to Results

Electromed Inc (ELMD)

Featured in High-Growth Small-Cap Stocks Small-Cap Stocks

Electromed, Inc. is a healthcare equipment company focused on airway clearance therapy and related products based on high frequency chest wall oscillation (HFCWO). Its portfolio includes the SmartVest airway clearance system for patients with impaired pulmonary function, such as those with bronchiectasis, cystic fibrosis, and certain neuromuscular or post-surgical conditions. The company also offers the SmartVest SQL System, the SmartVest Clearway System, and SmartVest Connect, a wireless platform designed to support data sharing between physicians and patients and help monitor therapy performance. In addition, Electromed supplies single-patient-use SmartVest and SmartVest Wrap products for acute care settings. The company sells its products to physicians, healthcare providers, and patients in the United States and international markets. Electromed was incorporated in 1992 and is headquartered in New Prague, Minnesota.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NYSE-ELMD
$34.05
-15.5% Downside
Fair
$40.33
0.1% Upside
Fair
Great
—
—
—
0.0%
September 1, 2026
33.4x
6.9x
4.7x
338.5 M
320.5 M
0.0%
82.7%
23.1
—
92.6%
Valuation • Fair Value

Electromed Inc (NYSE-ELMD) Fair Value by Valuation Model

Compare the primary fair value estimate for Electromed Inc (NYSE-ELMD) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$34.05

Estimated downside of 15.5% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$34.71

Discounted cash flow valuation reference.

Ben Graham Formula Value

$13.54

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$33.40

Comparable-company valuation reference.

Analyst Price Target

$40.33

Analysts imply upside of 0.1%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Electromed Inc (NYSE-ELMD) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Electromed Inc (NYSE-ELMD)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

71.752 M

Current operating scale indicator.

Revenue Forecast

73.5 M

Forward revenue estimate.

EBITDA

14.509 M

Current operating profitability reference.

EBITDA Forecast

17.4 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Electromed Inc (NYSE-ELMD) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Electromed Inc (NYSE-ELMD)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Great

Positive financial-health read.

Piotroski Score

7

Relatively strong quality score.

Beneish M-Score

-2.28

No elevated caution signal from this screen.

Altman Z-Score

23.1

Relatively strong balance-sheet zone.

FCF / Net Income

92.6%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Electromed Inc (NYSE-ELMD). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Electromed Inc (NYSE-ELMD)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

September 1, 2026

Days to Earnings

42

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Electromed Inc (NYSE-ELMD), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Electromed Inc (NYSE-ELMD) Stock Forecast & Technical Outlook

Review Electromed Inc (NYSE-ELMD) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Electromed Inc (NYSE-ELMD) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Electromed Inc (NYSE-ELMD) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Sell

The daily technical read for Electromed Inc (NYSE-ELMD) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Electromed Inc (NYSE-ELMD) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Electromed Inc (NYSE-ELMD) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Electromed Inc (NYSE-ELMD)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Electromed Inc (NYSE-ELMD) has a Strong Buy consensus, with 3 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 3
Hold 0
Sell 0
FAQ • Fast Investor Answers

Electromed Inc (NYSE-ELMD) Stock FAQ

Quick answers about Electromed Inc (NYSE-ELMD) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$34.05
Estimated downside 15.5%
Valuation Rating
Overvalued
Estimated downside of 15.5%
Analyst Target
$40.33
Implied upside 0.1%
Financial Health
Great
Current financial-health read

The current fair value estimate for Electromed Inc (NYSE-ELMD) is $34.05. This implies an estimated downside of 15.5% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 15.5% versus the current market price.

The available analyst price target for Electromed Inc (NYSE-ELMD) is $40.33. The analyst target implies estimated upside of 0.1%.

The current financial health read for Electromed Inc (NYSE-ELMD) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Electromed Inc (NYSE-ELMD) is September 1, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Electromed Inc (NYSE-ELMD) is 33.4x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Electromed Inc is 338.5 M.

The current enterprise value listed for Electromed Inc is 320.5 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Electromed Inc is NYSE-ELMD, and the stock is listed on NYSE.

Electromed Inc (NYSE-ELMD) is listed on NYSE.

The current debt-to-total-capital ratio listed for Electromed Inc is 0.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Electromed Inc is 82.7%. Free float helps investors understand how much of the share base is available for public trading.

Similar Healthcare Equipment & Supplies Stocks on NYSE View more

Abbott Laboratories (ABT) Abbott Laboratories (ABT)
Stryker Corporation (SYK) Stryker Corporation (SYK)
Medtronic PLC (MDT) Medtronic PLC (MDT)
Boston Scientific Corp (BSX) Boston Scientific Corp (BSX)
Edwards Lifesciences Corp (EW) Edwards Lifesciences Corp (EW)
Becton Dickinson and Co (BDX) Becton Dickinson and Co (BDX)
Alcon AG (ALC) Alcon AG (ALC)
ResMed Inc (RMD) ResMed Inc (RMD)
Koninklijke Philips NV ADR (PHG) Koninklijke Philips NV ADR (PHG)
STERIS plc (STE) STERIS plc (STE)
Zimmer Biomet Holdings Inc (ZBH) Zimmer Biomet Holdings Inc (ZBH)
Solventum Corp (SOLV) Solventum Corp (SOLV)
Smith & Nephew SNATS Inc (SNN) Smith & Nephew SNATS Inc (SNN)
Penumbra Inc (PEN) Penumbra Inc (PEN)
Baxter International Inc (BAX) Baxter International Inc (BAX)
Globus Medical (GMED) Globus Medical (GMED)
Glaukos Corp (GKOS) Glaukos Corp (GKOS)
Teleflex Incorporated (TFX) Teleflex Incorporated (TFX)
Bausch + Lomb Corp (BLCO) Bausch + Lomb Corp (BLCO)
Envista Holdings Corp (NVST) Envista Holdings Corp (NVST)
Haemonetics Corporation (HAE) Haemonetics Corporation (HAE)
Integer Holdings Corp (ITGR) Integer Holdings Corp (ITGR)
Butterfly Network, Inc (BFLY) Butterfly Network, Inc (BFLY)
Enovis Corp (ENOV) Enovis Corp (ENOV)